Eloxx Pharmaceuticals adds former Pfizer executive to its board

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) announced the appointment of Geno Germano to its Board of Directors, effective Oct. 19, 2026, according to a company press release.

Germano brings more than 35 years of biopharmaceutical experience, including roles at Pfizer Inc., where he served as Group President of the Global Innovative Pharmaceutical business, overseeing an approximately $14 billion portfolio and the late-stage development of more than a dozen drug candidates across five therapeutic areas.

He also previously served as President and Chief Executive Officer of Elucida Oncology, Inc. and as President of Intrexon Corporation, now known as Precigen, Inc. Earlier in his career, he held senior positions at Wyeth and Johnson & Johnson.

Germano currently serves as Chairman of the Board of Directors of Entera Bio Ltd. and as a board member of Precision BioSciences, Inc. and Harmony Biosciences Holdings, Inc.

"Geno is an accomplished biopharmaceutical leader whose experience developing and commercializing medicines at global scale, and guiding emerging companies through pivotal stages of growth, will be invaluable to Eloxx," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Eloxx is a clinical-stage company developing exaluren, a small-molecule product candidate, for the treatment of rare kidney diseases including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease.

You May Also Be Interested In

• Winnebago plans board nominee, board declassification vote
• Bolt Biotherapeutics acquires Prana Therapies, raises $120M
• Perspective Therapeutics reports Phase 1/2a trial data for NET drug